sertraline and sumatriptan

Pharmacodynamic interaction: both sertraline (a selective serotonin reuptake inhibitor) and sumatriptan (a 5-HT1B/1D receptor agonist) increase serotonergic activity. The additive effect can lead to excessive serotonin in the central nervous system and periphery, causing serotonin syndrome.

Patients may develop serotonin syndrome, which presents with altered mental status, autonomic instability (tachycardia, hypertension, hyperthermia), and neuromuscular abnormalities (clonus, hyperreflexia, tremors). The onset can be rapid, and severe cases can lead to seizures, rhabdomyolysis, or death. The risk is increased with higher doses or when other serotonergic drugs are co-administered.

If co-prescription is necessary, monitor patients closely for signs and symptoms of serotonin syndrome. Counsel the patient to seek immediate medical attention if they experience agitation, hallucinations, rapid heart rate, fever, muscle twitching, or diarrhea. Consider alternative migraine therapy with a drug lacking serotonergic activity, such as a nonsteroidal anti-inflammatory agent or an antiemetic. If serotonin syndrome is suspected, stop both drugs and initiate supportive care. Ensure the patient's history is reviewed for other serotonergic medications.

This is a well-recognized interaction based on pharmacodynamic principles and numerous case reports of serotonin syndrome with SSRIs and triptans. Regulatory agencies and clinical guidelines acknowledge the risk and recommend caution. However, the interaction is not considered an absolute contraindication, and the severity of the reaction varies among patients.